Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1)

Vaccine

Volumn 26, Issue 51, 2008, Pages 6550-6554

  Harvey, Ruth ^a   Wheeler, Jun X ^a   Wallis, Chantal L ^a   Robertson, James S ^a   Engelhardt, Othmar G ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Haemagglutinin; Influenza; Vaccine

Indexed keywords

INFLUENZA VACCINE; MATRIX PROTEIN; VIRUS HEMAGGLUTININ; VIRUS NUCLEOPROTEIN;

ANTIGEN EXPRESSION; ARTICLE; DEGLYCOSYLATION; INFLUENZA VIRUS A H5N1; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; QUANTITATIVE ANALYSIS; VACCINE PRODUCTION;

ANTIGENS, VIRAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; VIRUS CULTIVATION;

EID: 58149177358     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.050     Document Type: Article

References (12)

1. Writing Committee of the Second World Health Organisation Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) virus. Update on Avian Influenza A (H5N1) Virus Infection in Humans. New Engl J Med 358 (2008) 261-273
2. Subbarao K., Chen H., Swayne D., Mingay L., Fodor E., Brownlee G., et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305 (2003) 192-200
3. Nicolson C., Major D., Wood J.M., and Robertson J.S. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 23 (2005) 2943-2952
4. Bresson J., Perronne C., Launay O., Gerdil C., Saville M., Wood J.M., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. The Lancet 367 (2006) 1657-1664
5. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. The Lancet 370 (2007) 580-589
6. Wood J.M., Schild G.C., Newman R.W., and Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 5 3 (1977) 237-247
7. Wood J.M., Mumford J.A., Dunleavy U., Seagroatt V., Newman R.W., Thornton D., and Schild G.C. Single radial immunodiffusion potency tests for inactivated equine influenza vaccines. Equine infectious diseases V (1988), The University Press of Kentucky p. 74-9
8. Kilbourne E.D. Future influenza vaccines and the use of genetic recombinants. Bull World Health Org 41 (1969) 643-645
9. Vipond C., Wheeler J.X., Jones C., Feavers I.M., and Suker J. Characterization of the protein content of a meningococcal outer membrane vesicle vaccine by polyacrylamide gel electrophoresis and mass spectrometry. Hum Vaccin 1 (2005) 80-84
10. Jin H., Leser G.P., Zhang J., and Lamb R.A. Influenza virus haemagglutinin and neuraminidase cytoplasmic tails control particle shape. EMBO 16 6 (1997) 1236-1247
11. Horimoto T., Murakami S., Muramoto Y., Yamada S., Fujii K., Kiso M., et al. Enhanced growth of seed viruses for H5N1 influenza vaccines. Virology 366 1 (2007) 23-27
12. WHO.H5N1 avian influenza: Vaccine research and development, 2005. http://www.who.int/csr/disease/avian_influenza/vaccineresearch2005_11_3/ en/index.html. (accessed 6th May 2008).